Can I switch this patient’s losartan (angiotensin II receptor blocker) to hydrochlorothiazide (HS) given a serum potassium of 3.1 mEq/L (hypokalemia)?

Do Not Switch Losartan to Hydrochlorothiazide Alone in This Patient

With a serum potassium of 3.1 mEq/L (hypokalemia), switching from losartan to hydrochlorothiazide (HCTZ) monotherapy would be dangerous and is contraindicated. HCTZ will worsen the existing hypokalemia, potentially leading to life-threatening cardiac arrhythmias.

Why This Switch Is Problematic

Hydrochlorothiazide Worsens Hypokalemia

• HCTZ causes significant potassium loss through increased renal excretion 1, 2
• The prevalence of hypokalemia among HCTZ users is 12.6% in the general population, but this patient already has severe hypokalemia (K+ 3.1 mEq/L) 1
• Hypokalemia should be avoided in patients treated with thiazide diuretic monotherapy (Grade C recommendation) 3, 4, 5
• Recent data shows HCTZ-induced hypokalemia is associated with increased cardiovascular events and mortality 2

Losartan Actually Helps Prevent Hypokalemia

• ARBs like losartan tend to increase or maintain serum potassium by blocking aldosterone effects 6
• In the HEAAL trial, high-dose losartan actually reduced the risk of hypokalemia (HR 0.77) in heart failure patients 7
• Hypokalemia (K+ ≤3.5 mEq/L) was associated with worse outcomes including increased cardiovascular death (HR 1.68) and sudden cardiac death (HR 1.74) 7

What You Should Do Instead

Immediate Management

1. Keep the patient on losartan - it's protective against further potassium loss
2. Correct the hypokalemia first before making any medication changes:
   • Target serum potassium to 4.0-5.0 mmol/L range 8
   • Use potassium supplementation with magnesium if needed 8
   • Consider adding a mineralocorticoid receptor antagonist (MRA) if appropriate 9

If Blood Pressure Control Is Inadequate

The correct approach is combination therapy, not switching:

• Add HCTZ to losartan rather than replacing it 3, 4, 5
• Canadian Hypertension Guidelines recommend combining ARB with thiazide diuretic as add-on therapy (Grade B) 3, 5
• Fixed-dose combination therapy (ARB + HCTZ) has the lowest risk of hypokalemia compared to monotherapy (adjusted OR 0.32) 1
• The combination of losartan 50mg/HCTZ 12.5mg actually improved glucose tolerance and did not worsen potassium levels in one study 10

Monitoring Requirements

When combining losartan with HCTZ:

• Check potassium and renal function 2-4 weeks after initiation or dose changes 11
• The Monte Carlo simulation predicts hypokalemia risk when baseline K+ is ≤4.3 mmol/L with HCTZ added to other therapy 12
• Consider prophylactic potassium-sparing agent (amiloride, spironolactone) when adding HCTZ 12, 2

Critical Pitfalls to Avoid

1. Never discontinue the ARB in favor of HCTZ monotherapy when hypokalemia exists - this will make it worse
2. Do not use thiazide diuretics as monotherapy when potassium is already low 3, 4
3. Avoid potassium-sparing diuretics during ACE inhibitor/ARB initiation but they are appropriate once therapy is established and hypokalemia persists 13
4. Women, ethnic minorities, and those on long-term therapy have higher risk of HCTZ-induced hypokalemia 1

The Evidence Hierarchy

The FDA drug label for losartan explicitly warns about hyperkalemia risk when combined with potassium-raising agents 6, confirming that losartan raises (not lowers) potassium. Multiple hypertension guidelines consistently state that hypokalemia should be avoided with thiazide monotherapy 3, 4, 5, 14. The 2025 ACC/AHA guidelines emphasize checking electrolytes 2-4 weeks after diuretic initiation and using combination therapy with complementary effects on electrolytes (e.g., ACEi/ARB plus thiazide to normalize potassium) 11.

Bottom line: Correct the hypokalemia first while maintaining losartan, then add HCTZ if needed for blood pressure control - never switch to HCTZ alone.